Cardiovascular effects of antipsychotics

References

• Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res.45(1–2), 21–28 (2000).
   PubMed Web of Science ®Google Scholar
• Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. Br. Med. J.321(7259), 483–484 (2000).
   PubMed Web of Science ®Google Scholar
• Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry58(9), 844–850 (2001).
   PubMed Web of Science ®Google Scholar
• Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chronic Dis.3(2), 1–14 (2006).
   Google Scholar
• Osborn PJ, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s general practice research database. Arch. Gen. Psychiatry64(2), 242–249 (2007).
   PubMed Web of Science ®Google Scholar
• Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust. NZ J. Psychiatry35(2), 196–202 (2001).
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs19(Suppl. 1), 1–95 (2005).
   PubMed Web of Science ®Google Scholar
• Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Safety23(3), 215–228 (2000).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Nasrallah HA (Eds). Medical Illness and Schizophrenia. American Psychiatric Press, Inc., DC, USA (2003).
   Google Scholar
• Marder SR, Essock SM, Miller AL et al. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry161(8), 1334–1349 (2004).
   PubMed Web of Science ®Google Scholar
• Coleman HN 3rd, Taylor RR, Pool PE et al. Congestive heart failure following chronic tachycardia. Am. Heart J.81(6), 790–798 (1971).
   PubMed Web of Science ®Google Scholar
• Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J. Am. Coll. Cardiol.29(4), 709–715 (1997).
   PubMed Web of Science ®Google Scholar
• Boettger S, Hoyer D, Falkenhahn K, Kaatz M, Yeragani VK, Bar K-J. Altered diurnal autonomic variation and reduced vagal information flow in acute schizophrenia. Clin. Neurophysiol.117(12), 2715–2722 (2006).
   PubMedGoogle Scholar
• Agelink MW, Malessa R, Kamcili E et al. Cardiovascular autonomic reactivity in schizophrenics under neuroleptic treatment: a potential predictor of short-term outcome? Neuropsychobiology38(1), 19–24 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen H, Loewenthal U, Matar M, Kotler M. Heart rate variability in schizophrenic patients treated with antipsychotic agents. Harefuah140(12), 1142–1147, 1231 (2001).
   PubMedGoogle Scholar
• Tuininga YS, van Veldhuisen DJ, Brouwer J et al. Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment. Br. Heart J.72(6), 509–513 (1994).
   PubMedGoogle Scholar
• Casey DE. The relationship of pharmacology to side effects. J. Clin. Psychiatry58(Suppl.) 1055–1062 (1997).
   Google Scholar
• Silver H, Kogan H, Zlotogorski D. Postural hypotension in chronically medicated schizophrenics. J. Clin. Psychiatry51(11), 459–462 (1990).
   PubMedGoogle Scholar
• Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin. Auton. Res.6(2), 125–126 (1996).
   PubMed Web of Science ®Google Scholar
• Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension19(6 Pt 1), 508–519 (1992).
   PubMed Web of Science ®Google Scholar
• Thapa PB, Gideon P, Fought RL, Ray WA. Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents. Am. J. Epidemiol.142(2), 202–211 (1995).
   PubMed Web of Science ®Google Scholar
• Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr. Bull.23(4), 567–582 (1997).
   PubMed Web of Science ®Google Scholar
• Tandon R. Safety and tolerability: how do newer generation “atypical” antipsychotics compare? Psychiatr. Q.73(4), 297–311 (2002).
   PubMed Web of Science ®Google Scholar
• Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet354(9193), 1841–1845 (1999).
   PubMed Web of Science ®Google Scholar
• Coulter DM, Bate A, Meyboom RH, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. Br. Med. J.322(7296), 1207–1209 (2001).
   PubMed Web of Science ®Google Scholar
• Hagg S, Spigset O, Bate A, Soderstrom TG. Myocarditis related to clozapine treatment. J. Clin. Psychopharmacol.21(4), 382–388 (2001).
   PubMed Web of Science ®Google Scholar
• Roh S, Ahn DH, Nam JH, Yang BH, Lee BH, Kim YS. Cardiomyopathy associated with clozapine. Exp. Clin. Psychopharmacol.14(1), 94–98 (2006).
   PubMed Web of Science ®Google Scholar
• Fitzsimons J, Lambert TJ, Dodd S et al. Clozapine and cardiotoxicity: echocardiography findings from Barwon Health. Schizophr. Res. Schizophr. Bull.33(2), 499 (2007).
   Google Scholar
• Meyer JM, Rao SD, Nielsen JR. Clozapine and dilated cardiomyopathy. Clinical Schizophrenia and Related Psychoses (2007) (In Press).
   Google Scholar
• Berk M, Fitzsimons J, Lambert T et al. Monitoring the safe use of clozapine: a consensus view from Victoria, Australia. CNS Drugs21(2), 117–127 (2007).
   PubMed Web of Science ®Google Scholar
• Kelly HG, Fay JE, Laverty SG. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can. Med. Assoc. J.89, 546–554 (1963).
   PubMed Web of Science ®Google Scholar
• Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. J. Clin. Psychiatry63(Suppl.) 95–111 (2002).
   PubMedGoogle Scholar
• Mehtonen OP, Aranko K, Malkonen L, Vapaatalo H. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr. Scand.84(1), 58–64 (1991).
   PubMed Web of Science ®Google Scholar
• Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch. Gen. Psychiatry58(12), 1161–1167 (2001).
   PubMed Web of Science ®Google Scholar
• Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry158(11), 1774–1782 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis R, Bagnall A, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst. Rev.(2), CD001715 (2000).
   Google Scholar
• Lindstrom E, Levander S. Sertindole: efficacy and safety in schizophrenia. Expert Opin. Pharmacother.7(13), 1825–1834 (2006).
   PubMed Web of Science ®Google Scholar
• Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J. Pharmacol. Exp. Ther.316(3), 1098–1106 (2006).
   PubMed Web of Science ®Google Scholar
• Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA294(15), 1934–1943 (2005).
   PubMed Web of Science ®Google Scholar
• Straus SM, Blooming GS, Dieleman JP et al. Antipsychotics and the risk of sudden cardiac death. Arch. Intern. Med.164(12), 1293–1297 (2004).
   PubMed Web of Science ®Google Scholar
• Giles TD, Maudlin RK. Death associated with ventricular arrhythmia and thioridazine hydrochloride. JAMA205(2), 108–110 (1968).
   PubMed Web of Science ®Google Scholar
• De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: a call for consensus. Eur. J. Clin. Psychopharmacol.57(3), 185–209 (2001).
   PubMed Web of Science ®Google Scholar
• Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N. Engl. J. Med.345(20), 1473–1482 (2001).
   PubMed Web of Science ®Google Scholar
• Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J. Am. Coll. Cardiol.2(5), 806–817 (1983).
   PubMed Web of Science ®Google Scholar
• Crumb WJ Jr, Ekins S, Sarazan RD et al. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm. Res.23(6), 1133–1143 (2006).
   PubMed Web of Science ®Google Scholar
• Brink PA, Crotti L, Corfield V et al. Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation112(17), 2602–2610 (2005).
   PubMed Web of Science ®Google Scholar
• Harrigan EP, Miceli JJ, Anziano R et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol.24(1), 62–69 (2004).
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Hanssens L, De Hert M, Wampers M, Reginster J-Y, Peuskens J. Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clin. Pract. Epidemol. Ment. Health2(11), 1–11 (2006).
   PubMedGoogle Scholar
• Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology31(10), 2091–2120 (2006).
   PubMedGoogle Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care30(Suppl. 1), S42–S47 (2007).
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care24, 683–689 (2001).
   PubMed Web of Science ®Google Scholar
• Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am. J. Med.115(Suppl. 8A), S6–S11 (2003).
   Web of Science ®Google Scholar
• Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and Type 2 diabetes mellitus. Arch. Intern. Med.165(2), 2644–2650 (2005).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA285(19), 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Alexander CM, Landsman PB, Teutsch SM et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes52(5), 1210–1214 (2003).
   PubMed Web of Science ®Google Scholar
• British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart91(Suppl. 5), 1–52 (2005).
   PubMed Web of Science ®Google Scholar
• Goff DC, Sullivan L, McEvoy JP et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE Study and matched controls. Schizophr. Res.80(1), 45–53 (2005).
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Nasrallah HA et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III. Schizophr. Res.80(1), 19–32 (2005).
   PubMed Web of Science ®Google Scholar
• Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci.71(3), 239–257 (2002).
   PubMed Web of Science ®Google Scholar
• Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry160(2), 284–289 (2003).
   PubMed Web of Science ®Google Scholar
• Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci.74(16), 1999–2008 (2004).
   PubMed Web of Science ®Google Scholar
• Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int. J. Obes. Relat. Metab. Disord.26(1), 137–141 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br. J. Psychiatry184, 58–62 (2004).
   PubMed Web of Science ®Google Scholar
• Arranz B, Rosel P, Ramirez N et al. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J. Clin. Psychiatry65(10), 1335–1342 (2004).
   PubMed Web of Science ®Google Scholar
• Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TMS. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. [Erratum appears in Can. J. Psychiatry51(8), 552 (2006)]. Can. J. Psychiatry51(6), 382–386 (2006).
   Google Scholar
• Cohn T, Prud’homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry49(11), 753–760 (2004).
   PubMed Web of Science ®Google Scholar
• Hagg S, Lindblow Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int. Clinical Psychopharmacol.21(2), 93–98 (2006).
   PubMed Web of Science ®Google Scholar
• De Hert MA, van Winkel R, van Eyck D et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res.83(1), 87–93 (2006).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Loh C, Leckband SG et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J. Psychiatr. Pract.12(1), 5–10 (2006).
   PubMedGoogle Scholar
• Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J. Clin. Psychiatry67(4), 575–583 (2006).
   PubMed Web of Science ®Google Scholar
• Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J. Clin. Psychiatry62(Suppl. 27), 27–34; discussion 40–41 (2001).
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology28(3), 519–526 (2003).
   PubMed Web of Science ®Google Scholar
• Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Natl Acad. Sci. USA104(9), 3456–3459 (2007).
   PubMed Web of Science ®Google Scholar
• Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and Type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med.4(10), 1152–1156 (1998).
   PubMed Web of Science ®Google Scholar
• McQuade RD, Stock E, Marcus R et al. Aripiprazole versus olanzapine in schizophrenia: a 52-week open-label extension study. Presented at: 43rd ACNP Annual Meeting. San Juan, PR, USA, 13 December 2004.
   Google Scholar
• De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int. Clinical Psychopharmacol.21(Suppl. 2), S11–S15 (2006).
   PubMed Web of Science ®Google Scholar
• Meyer JM. Novel antipsychotics and severe hyperlipidemia. J. Clin. Psychopharmacol.21(4), 369–374 (2001).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res.70(1), 1–17 (2004).
   PubMed Web of Science ®Google Scholar
• Casey DE, Carson WH, Saha AR et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology166, 391–399 (2003).
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Loebel A, Yang R, Lebovitz H. Course of weight and metabolic benefits 1 year after switching to ziprasidone. Presented at: American Psychiatric Association Annual Meeting. NY, USA, 5 May 2004.
   Google Scholar
• Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, Klungel OH, Porsius AJ, de Boer A. Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Safety24(6), 443–456 (2001).
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. [See comment]. [Summary for patients in Ann. Intern. Med.139(10), I16; PMID: 14623638 (2003)]. Ann. Intern. med.139(10), 802–809 (2003).
   Google Scholar
• Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology32(2), 289–297 (2007).
   PubMed Web of Science ®Google Scholar
• Vestri H, Maianu L, Moellering DR, Garvery WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology32(4), 765–772 (2007).
   PubMed Web of Science ®Google Scholar
• Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study [see comments]. [Published erratum appears in Circulation97(19), 1995 (1998)]. Circulation97(11), 1029–1036 (1998).
   Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. J. Clin. Psychiatry65(2), 267–272 (2004).
   PubMed Web of Science ®Google Scholar
• De Hert M, Kalnicka D, van Winkel R et al. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry67(12), 1889–1896 (2006).
   PubMedGoogle Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med.339(4), 229–234 (1998).
   PubMed Web of Science ®Google Scholar
• Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr. Res.71(2–3), 195–212 (2004).
   PubMed Web of Science ®Google Scholar
• Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am. J. Med.111(9), 716–723 (2001).
   PubMed Web of Science ®Google Scholar
• Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry14(1), 59–64 (2002).
   PubMedGoogle Scholar
• Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy22(7), 841–852 (2002).
   PubMed Web of Science ®Google Scholar
• Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy23(6), 735–744 (2003).
   PubMed Web of Science ®Google Scholar
• Koller E, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J. Clin. Psychiatry65(6), 857–863 (2004).
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry163(4), 611–622 (2006).
   PubMed Web of Science ®Google Scholar
• Henderson DC, Nguyen DD, Copeland PM et al. Clozapine, diabetes mellitus, hyperlipidemia and cardiovascular risks and mortality: results of a 10-year naturalistic study. J. Clin. Psychiatry66(9), 1116–1121 (2005).
   PubMed Web of Science ®Google Scholar
• Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can. J. Psychiatry51(8), 492–501 (2006).
   PubMed Web of Science ®Google Scholar